

## **Oxurion Receives Transparency Notification from Fidelity Management & Research Company LLC**

**Leuven, BELGIUM, Boston, MA, US – November 4, 2022 – 7 PM CET** [Oxurion NV](#) (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation<sup>1</sup> it has received transparency notification following the issuance of new shares pursuant to the Capital Commitment entered into with Negma Group.

Oxurion received a transparency notification from Fidelity Management & Research Company LLC, indicating that by virtue of a downward passive crossing of a threshold, its 3,128,819 common shares have crossed below the 5% threshold.

### **Content of the Fidelity Notification**

#### *Reason of the notification*

Passive crossing of a threshold

#### *Notifications by*

A parent undertaking or a controlling person

#### *Threshold that is crossed*

5%

#### *Denominator*

66,675,765

#### *Notified details*

See Annex 1

#### *Chain of controlled undertakings through which the holding is effectively held*

Fidelity Management & Research Company LLC is controlled by FMR LLC.

FMR LLC is not a controlled entity

### **About Oxurion**

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed

as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at [www.oxurion.com](http://www.oxurion.com).

**Important information about forward-looking statements**

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

**For further information please contact:**

<p><u>Oxurion NV</u> Tom Graney Chief Executive Officer Tel: +32 16 75 13 10 <a href="mailto:tom.graney@oxurion.com">tom.graney@oxurion.com</a></p> <p>Michael Dillen Chief Business Officer Tel: +32 16 75 13 10 <a href="mailto:michael.dillen@oxurion.com">michael.dillen@oxurion.com</a></p>	<p><u>US</u> <u>Conway Communications</u> Beth Kurth <a href="mailto:bkurth@conwaycommsir.com">bkurth@conwaycommsir.com</a></p> <p><u>ICR Westwicke</u> Christopher Brinzey Tel: +1 617 835 9304 <a href="mailto:Chris.Brinzey@westwicke.com">Chris.Brinzey@westwicke.com</a></p>
--	---

**ANNEX 1**

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
FMR LLC	0	0		0.00%	
Fidelity Management & Research Company LLC	3,128,819	3,038,418		4.56%	
Subtotal	3,128,819	3,038,418		4.56%	
<b>TOTAL</b>		<b>3,038,418</b>	<b>0</b>	<b>4.56%</b>	<b>0.00%</b>

B) Equivalent financial instruments	After the transaction					
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
Fidelity Management & Research Company LLC	Stock Loan			90,401	0.14%	physical
<b>TOTAL</b>				<b>90,401</b>	<b>0.14%</b>	

TOTAL (A & B)	# of voting rights	% of voting rights
<b>CALCULATE</b>	<b>3,128,819</b>	<b>4.69%</b>

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.